The article discusses recent advancements in targeting the RAS family of proteins, particularly KRAS, which is a common driver of cancer. KRAS has long been considered undruggable due to its structure, but recent developments in bioengineering and chemistry have enabled direct targeting. Two KRAS G12C inhibitors, sotorasib and adagrasib, have been approved for non-small cell lung cancer (NSCLC) and show promise in other cancers. These inhibitors target the 'on' and 'off' states of KRAS, with the 'off' state inhibitors trapping KRAS in an inactive state. However, resistance mechanisms, including genetic mutations and adaptive feedback loops, pose challenges. Emerging strategies include combination therapies with other drugs, such as EGFR inhibitors, and novel approaches like pan-RAS inhibitors and PROTAC technology. Additionally, immunotherapeutic strategies are being explored to enhance the effectiveness of KRAS targeting. Despite progress, challenges remain in overcoming resistance and ensuring the safety and efficacy of these therapies. The article highlights ongoing clinical trials and the need for further research to optimize KRAS-targeted treatments.The article discusses recent advancements in targeting the RAS family of proteins, particularly KRAS, which is a common driver of cancer. KRAS has long been considered undruggable due to its structure, but recent developments in bioengineering and chemistry have enabled direct targeting. Two KRAS G12C inhibitors, sotorasib and adagrasib, have been approved for non-small cell lung cancer (NSCLC) and show promise in other cancers. These inhibitors target the 'on' and 'off' states of KRAS, with the 'off' state inhibitors trapping KRAS in an inactive state. However, resistance mechanisms, including genetic mutations and adaptive feedback loops, pose challenges. Emerging strategies include combination therapies with other drugs, such as EGFR inhibitors, and novel approaches like pan-RAS inhibitors and PROTAC technology. Additionally, immunotherapeutic strategies are being explored to enhance the effectiveness of KRAS targeting. Despite progress, challenges remain in overcoming resistance and ensuring the safety and efficacy of these therapies. The article highlights ongoing clinical trials and the need for further research to optimize KRAS-targeted treatments.